Sensitivity and Specificity of International Prostate Symptom Score (IPSS) for the Screening of Iranian Patients with Prostate Cancer
,
Abstract
We assessed the lower urinary tract symptoms (LUTS) in prostatic cancer patients and investigated the sensitivity and specificity of international prostate symptom score (IPSS) in the screening of these patients. A total number of 132 prostatic cancer patients as the case group who were confirmed by the pathologists and 101 noncancerous men as the control group, aged 50 or older, responded to a questionnaire which included seven questions regarding urination, named the International Prostate Symptom Score (IPSS). Then, two groups were assessed and compared with each other and also the sensitivity and specificity of IPSS tool for screening of prostatic cancer patients were calculated. All participants filled out the questionnaire. 60 (59.4%) noncancerous men and 29 (22.0%) cases had mild LUTS, and 41 (40.6%) noncancerous men and 103 (78.0%) cases had moderate to severe LUTS. Moreover, the sensitivity and specificity of the IPSS tool were 78% and 59.4%, respectively. Urination status and problems could be easily assessed by IPSS and it is a sensitive and specific tool for screening of prostatic cancer patients. It appears that IPSS is a cost beneficial, sensitive, specific and easily-used screening tool to diagnose the prostate cancer cases. Therefore, it can be used more extensively by the health care providers as well as by men ≥50 years old themselves.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-30.
Godley PA, Carpenter WR. Case-control prostate cancer screening studies should not exclude subjects with lowernurinary tract symptoms. J Clin Epidemiol 2007;60(2):176-80.
Hosseini M, SeyedAlinaghi S, Mahmoudi M, McFarland W. A case-control study of risk factors for prostate cancer in Iran. Acta Med Iran 2010;48(1):61-6.
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147(3 Pt 2):815-6.
Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, Mostofi FK. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994;74(5):1615-20.
Brawer MK, Meyer GE, Letran JL, Bankson DD, MorrisDL, Yeung KK, Allard WJ. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52(3):372-8.
Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E. "Quality of life" assessment of urination in elderly Japanese men and women with some medical problems using International Prostate Symptom Score and King's Health Questionnaire. Eur Urol 2002;41(4):411-9.
Pinnock C, Marshall VR. Troublesome lower urinary tract symptoms in the community: a prevalence study. Med J Aust 1997;167(2):72-5.
Tsukamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, Guess HA, Jacobsen SJ, Lieber MM. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995;154(2 Pt 1):391-5.
Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999;83(4):410-5.
Madersbacher S, Pycha A, Klingler CH, Schatzl G, Marberger M. The International Prostate Symptom score in both sexes: a urodynamics-based comparison. Neurourol Urodyn 1999;18(3):173-82.
Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. p. 525-33.
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148(5):1549-57; discussion 1564.
Chai TC, Belville WD, McGuire EJ, Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993;150(5 Pt 2):1710-3.
Chancellor MB, Rivas DA. American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostate hyperplasia. J Urol 1993;150(5 Pt 2):1706-8; discussion 1708-9.
van Haarst EP, Heldeweg EA, Newling DW, Schlatmann TJ. A cross-sectional study of the international prostate symptom scores related to age and gender in Dutch adults reporting no voiding complaints. Eur Urol 2005;47(3):334-9.
Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E. The relationships among filling, voiding subscores from International Prostate Symptom Score and quality of life in Japanese elderly men and women. Eur Urol 2002;42(5):498-505.
Sommer P, Nielsen KK, Bauer T, Kristensen ES, Hermann GG, Steven K, Nordling J. Voiding patterns in men evaluated by a questionnaire survey. Br J Urol 1990;65(2):155-60.
| Files | ||
| Issue | Vol 49, No 7 (2011) | |
| Section | Articles | |
| Keywords | ||
| International Prostate Symptom Score Prostate cancer Sensitivity Specificity | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
